Read more

August 31, 2020
1 min read
Save

Top psych stories of August: Botox injections and depression, yoga for anxiety and more

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio Psychiatry has compiled a list of its five most-viewed stories in August.

A study on the role of Botox injections in depression reduction, research on reducing anxiety via Kundalini yoga and MRI data on CBD’s ability to increase memory-related blood flow were just some of the most-read stories on Healio Psychiatry for the month.

Which story resonated with you most? Leave a comment or write to us on Twitter @HealioPsych.

Botox injections may reduce depression

Individuals who received Botox injections were significantly less likely to report depression vs. those who received different treatments, according to study results published in Scientific Reports. Read more.

Kundalini yoga effective for reducing anxiety

Kundalini yoga appeared effective for reducing anxiety, but cognitive behavioral therapy should remain first-line treatment, according to results of a randomized clinical trial published in JAMA Psychiatry. Read more.

CBD linked to increased blood flow to memory-related brain regions

Cannabidiol appeared to increase cerebral blood flow to brain regions involved in memory processing, according to results of an MRI study published in Journal of Psychopharmacology. Read more.

COVID-19 disproportionately affecting mental, physical health of families with children

Measures to combat the spread of COVID-19 may be having a significant negative impact on the mental and physical well-being of parents and their children, according to results of a survey study published in Pediatrics. Read more.

FDA approves supplemental new drug application for Spravato

The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of a supplemental new drug application for Spravato CIII nasal spray for the rapid reduction of depressive symptoms. Read more.